EP1601357A4 - Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese - Google Patents

Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese

Info

Publication number
EP1601357A4
EP1601357A4 EP04719237A EP04719237A EP1601357A4 EP 1601357 A4 EP1601357 A4 EP 1601357A4 EP 04719237 A EP04719237 A EP 04719237A EP 04719237 A EP04719237 A EP 04719237A EP 1601357 A4 EP1601357 A4 EP 1601357A4
Authority
EP
European Patent Office
Prior art keywords
synthesis
methods
kinase inhibitors
heterocyclic kinase
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04719237A
Other languages
German (de)
English (en)
Other versions
EP1601357A1 (fr
Inventor
M Arshad Siddiqui
David Belanger
Chaoyang Dai
Lianyun Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP1601357A1 publication Critical patent/EP1601357A1/fr
Publication of EP1601357A4 publication Critical patent/EP1601357A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP04719237A 2003-03-10 2004-03-10 Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese Withdrawn EP1601357A4 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US45345703P 2003-03-10 2003-03-10
US453457P 2003-03-10
US46091003P 2003-04-07 2003-04-07
US460910P 2003-04-07
US46302503P 2003-04-15 2003-04-15
US463025P 2003-04-15
US50271003P 2003-09-12 2003-09-12
US502710P 2003-09-12
PCT/US2004/007286 WO2004080463A1 (fr) 2003-03-10 2004-03-10 Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese

Publications (2)

Publication Number Publication Date
EP1601357A1 EP1601357A1 (fr) 2005-12-07
EP1601357A4 true EP1601357A4 (fr) 2007-10-03

Family

ID=32996376

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04719237A Withdrawn EP1601357A4 (fr) 2003-03-10 2004-03-10 Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese

Country Status (5)

Country Link
EP (1) EP1601357A4 (fr)
JP (1) JP2006519846A (fr)
CA (1) CA2518398A1 (fr)
MX (1) MXPA05009722A (fr)
WO (1) WO2004080463A1 (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CN101287727A (zh) 2005-08-17 2008-10-15 先灵公司 新的高亲和力喹啉基激酶配体
EP3719018A1 (fr) 2006-04-25 2020-10-07 Astex Therapeutics Ltd Dérivés de purine et de déazapurine comme composés pharmaceutiques
US7511063B2 (en) * 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
US7964732B2 (en) 2006-11-17 2011-06-21 Pfizer Inc. Substituted bicyclocarboxyamide compounds
JP5031846B2 (ja) 2006-12-07 2012-09-26 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ（５ａ）受容体アンタゴニストとしての２−アミノキノリン
CA2680625C (fr) 2007-03-14 2016-02-23 Ranbaxy Laboratories Limited Derives de pyrazolo(3,4-b)pyridine comme inhibiteurs de phosphodiesterase
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
JP2010528007A (ja) * 2007-05-23 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピロリジンオレキシン受容体アンタゴニスト
EP2559686A1 (fr) * 2007-08-22 2013-02-20 Allergan, Inc. Dérivés de naphtalène et de quinoline thérapeutique
WO2009040290A1 (fr) * 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Dérivés de quinoline utilisés comme antagonistes du récepteur 5ht5a
PT2201012E (pt) 2007-10-11 2014-09-04 Astrazeneca Ab Derivados de pirrolo[2,3-d]piridina como inibidores da proteína quinase b
US8329691B2 (en) 2007-10-15 2012-12-11 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
MX2010004819A (es) 2007-11-02 2010-07-05 Vertex Pharma Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta.
WO2009095752A1 (fr) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Dérivés de pyrazole condensés en tant que modulateurs du récepteur cannabinoïde
EP2262789A1 (fr) * 2008-03-05 2010-12-22 F. Hoffmann-La Roche AG 2-aminoquinoléines
AU2009221389A1 (en) 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-Aminoquinoline derivatives
CA2711247A1 (fr) * 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinoleines
AU2009224760A1 (en) * 2008-03-12 2009-09-17 F. Hoffmann-La Roche Ag 2-Aminoquinolines as 5-HT5A receptor antagonists
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
RU2529019C2 (ru) 2009-02-27 2014-09-27 Эмбит Байосайенсиз Корпорейшн Модулирующие jak киназу хиназолиновые производные и способы их применения
WO2010101949A1 (fr) * 2009-03-02 2010-09-10 Sirtris Pharmaceuticals, Inc. Quinoléines substituées en 8 et analogues associés utilisés comme modulateurs de sirtuine
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
WO2010143169A2 (fr) * 2009-06-12 2010-12-16 Société Splicos Composés s'utilisant dans le traitement du sida
EA022494B1 (ru) 2009-12-17 2016-01-29 Мерк Шарп Энд Домэ Корп. Соединения хинолинамида в качестве положительных аллостерических модуляторов мускаринового рецептора m1
JP5629331B2 (ja) 2010-01-29 2014-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ナフチリジン及びｓｙｋキナーゼ阻害剤としてのその使用
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
MX2013000748A (es) * 2010-08-27 2013-03-05 Gruenenthal Gmbh 2-amino-quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
JP5901634B2 (ja) 2010-09-01 2016-04-13 アムビト ビオスシエンセス コルポラチオン キナゾリン化合物及びその使用方法
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase
EP2684167B1 (fr) * 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions et méthodes utiles dans le traitement de maladies
EP3620159A1 (fr) 2011-04-01 2020-03-11 Astrazeneca AB Traitement thérapeutique
CA2834062A1 (fr) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridylaminopyridines en tant qu'inhibiteurs de syk
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
US9290490B2 (en) 2011-05-10 2016-03-22 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
MX336224B (es) 2011-07-26 2016-01-12 Boehringer Ingelheim Int Quinolinas sustituidas y su uso como medicamentos.
WO2013052394A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 2-pyridyl carboxamide
EP2763975B1 (fr) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
WO2013052391A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide
FI2785349T4 (fi) 2011-11-30 2023-02-09 Syövän yhdistelmähoito
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013192128A1 (fr) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Analogues d'imidazolyle en tant qu'inhibiteurs de syk
US20150150869A1 (en) 2012-06-20 2015-06-04 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2863914B1 (fr) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Dérivés de pyrazolyle en tant qu'inhibiteurs de syk
EP2863916B1 (fr) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Inhibiteurs à pyridine substituée de la tyrosine kinase de la rate (syk)
WO2013192088A1 (fr) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées
WO2014031438A2 (fr) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
EP2900665B1 (fr) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Dérivés triazolyle en tant qu'inhibiteurs de la syk
EP2922544B1 (fr) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Méthodes et compositions utiles dans le traitement de maladies faisant appel à des protéines de la famille bcl-2 avec des dérivés de quinoléine
EP2757161A1 (fr) 2013-01-17 2014-07-23 Splicos miRNA-124 comme biomarqueur de l'infection virale
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
EP3083559B1 (fr) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Composés aminohétéroaryles à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
WO2015095444A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés aminohétéroaryle à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
EP3082807B1 (fr) 2013-12-20 2018-07-04 Merck Sharp & Dohme Corp. Composés aminohétéroaryle à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
EP2974729A1 (fr) 2014-07-17 2016-01-20 Abivax Dérivés de quinoléine utilisés dans le traitement de maladies inflammatoires
WO2016067112A1 (fr) * 2014-10-31 2016-05-06 Genoscience Pharma 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
ES2849560T3 (es) * 2016-05-04 2021-08-19 Genoscience Pharma Sas Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas
CA3065114A1 (fr) * 2017-06-14 2018-12-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Inhibiteur de syk et procede d'utilisation correspondant
WO2019023278A1 (fr) * 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. Modulateurs de la somatostatine et utilisations de ces derniers
EP3620164A1 (fr) * 2018-09-05 2020-03-11 Genoscience Pharma SAS 2,4 diamino-quinoline substituée en tant que nouveau médicament destiné à la fibrose, l'autophagie et des maladies liées aux cathepsines b (ctsb), l (ctsl) et d (ctsd)
SG11202106210QA (en) 2018-12-14 2021-07-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Salt of syk inhibitor and crystalline form thereof
EP3669873A1 (fr) 2018-12-20 2020-06-24 Abivax Dérivés de quinoline destinés à être utilisés dans le traitement de maladies inflammatoires
WO2021257863A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
WO2021257857A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés naphtyridinone en tant qu'inhibiteurs de jak2 v617f
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
JP2024507935A (ja) 2021-02-25 2024-02-21 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としてのスピロ環式ラクタム
WO2023099589A1 (fr) * 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs d'irap à utiliser pour le traitement de maladies inflammatoires

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE537104C (de) * 1926-05-04 1933-03-17 Chem Ind Basel Verfahren zur Darstellung von substituierten Chinolincarbonsaeureamiden
DE858698C (de) * 1951-02-09 1952-12-08 Basf Ag Verfahren zur Herstellung von Pyridin- und Chinolinderivaten
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
WO1998018782A1 (fr) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited Derives de 2-pyrimidineamine et procedes de preparation
WO2002014269A2 (fr) * 2000-08-16 2002-02-21 Neurogen Corporation Derives pyridine 2,4-substitues
WO2003078404A1 (fr) * 2002-03-15 2003-09-25 Novartis Ag Derives de pyrimidine
WO2004002960A1 (fr) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Antagonistes du recepteur ccr5 a base de quinoleine substitues
WO2004081531A2 (fr) * 2003-03-10 2004-09-23 Schering Corporation Analyse de ligands

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472066A (en) * 1949-06-07 Z-arylamino-x-halogenoqtjinolines
FR6103M (fr) * 1967-02-22 1968-06-10
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPH05310702A (ja) * 1992-05-06 1993-11-22 Kyowa Hakko Kogyo Co Ltd 抗炎症剤、免疫調整剤およびキノリン−２，４−ジカルボン酸ジアミド誘導体
AU1251499A (en) * 1997-11-26 1999-06-15 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
US6303593B1 (en) * 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
AU6051800A (en) * 1999-06-16 2001-01-02 University Of Iowa Research Foundation, The Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US6593324B2 (en) * 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
BR0209957A (pt) * 2001-05-21 2004-03-30 Hoffmann La Roche Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0102858D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE537104C (de) * 1926-05-04 1933-03-17 Chem Ind Basel Verfahren zur Darstellung von substituierten Chinolincarbonsaeureamiden
DE858698C (de) * 1951-02-09 1952-12-08 Basf Ag Verfahren zur Herstellung von Pyridin- und Chinolinderivaten
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
WO1998018782A1 (fr) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited Derives de 2-pyrimidineamine et procedes de preparation
WO2002014269A2 (fr) * 2000-08-16 2002-02-21 Neurogen Corporation Derives pyridine 2,4-substitues
WO2003078404A1 (fr) * 2002-03-15 2003-09-25 Novartis Ag Derives de pyrimidine
WO2004002960A1 (fr) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Antagonistes du recepteur ccr5 a base de quinoleine substitues
WO2004081531A2 (fr) * 2003-03-10 2004-09-23 Schering Corporation Analyse de ligands

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HASEBE, M.; ET AL., TETRAHEDRON LETTERS, vol. 29, no. 48, 1988, pages 6287 - 6290, XP002445489 *
ILLUMINATI, G.; GILMAN, H., J. AM. CHEM. SOC., vol. 71, 1949, pages 3349 - 3351, XP002445491 *
SARGENT, H., J. AM. CHEM. SOC., vol. 68, 1964, pages 2688 - 2692, XP002445490 *
See also references of WO2004080463A1 *
WEISS, M.J.; HAUSER, C.R., J. AM. CHEM. SOC., vol. 71, 1949, pages 2026 - 2027, XP002445492 *

Also Published As

Publication number Publication date
WO2004080463A1 (fr) 2004-09-23
CA2518398A1 (fr) 2004-09-23
MXPA05009722A (es) 2006-03-09
JP2006519846A (ja) 2006-08-31
EP1601357A1 (fr) 2005-12-07

Similar Documents

Publication Publication Date Title
EP1601357A4 (fr) Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese
AU2003251559A8 (en) Heterocyclic inhibitors of kinases
IL173936A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
IL181524A0 (en) Heterocyclic compounds and methods of use
PL376789A1 (pl) Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
EG27049A (en) P38 inhibitors and methods of use thereof
PL376575A1 (pl) Podstawione związki heterocykliczne oraz sposoby wykorzystania
IL174431A0 (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
HK1072545A1 (en) Novel inhibitors of kinases
AU2003303128A8 (en) Inhibitors and methods of use thereof
PL378432A1 (pl) Inhibitory p38 i sposoby ich zastosowania
IL176233A0 (en) Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
HK1160859A1 (en) Inhibitors of tyrosine kinases
IL208249A0 (en) Spirocyclic heterocyclic derivatives and methods of their use
EP1691812A4 (fr) Inhibiteurs de gtpase et procedes d'utilisation correspondants
EP1789437A4 (fr) Inhibiteurs de npc1l1 et npc1l1 et procédés d'utilisation associés
EP1678157A4 (fr) Composes heterocycliques, leurs procedes de fabrication et leur utilisation
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
HK1077520A1 (zh) 用作p38促細胞分裂原活化蛋白激酶抑制劑的吲哚類衍生物
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
EP1670422A4 (fr) Identification d'inhibiteurs de kinase
GB0511267D0 (en) Indol derivatives and their use as kinase inhibitors
ZA200500492B (en) Novel inhibitors of kinases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050913

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077021

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070830

17Q First examination report despatched

Effective date: 20080603

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100529

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077021

Country of ref document: HK